Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBT Margin (2016 - 2025)

Historic EBT Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 24.96%.

  • Gyre Therapeutics' EBT Margin rose 95400.0% to 24.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.24%, marking a year-over-year increase of 883400.0%. This contributed to the annual value of 21.95% for FY2024, which is 897900.0% up from last year.
  • As of Q3 2025, Gyre Therapeutics' EBT Margin stood at 24.96%, which was up 95400.0% from 8.36% recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' EBT Margin peaked at 45.93% during Q1 2024, and registered a low of 1830.73% during Q1 2022.
  • In the last 5 years, Gyre Therapeutics' EBT Margin had a median value of 8.36% in 2025 and averaged 424.65%.
  • As far as peak fluctuations go, Gyre Therapeutics' EBT Margin crashed by -15035900bps in 2021, and later soared by 18558800bps in 2023.
  • Quarter analysis of 5 years shows Gyre Therapeutics' EBT Margin stood at 832.34% in 2021, then surged by 97bps to 22.46% in 2022, then crashed by -1544bps to 369.38% in 2023, then surged by 101bps to 2.77% in 2024, then skyrocketed by 801bps to 24.96% in 2025.
  • Its EBT Margin stands at 24.96% for Q3 2025, versus 8.36% for Q2 2025 and 21.01% for Q1 2025.